Correlated Drug Terms (1)

---

	Name (Synonyms)	Correlation
drug1149	IMM-101 Wiki	0.71

Correlated MeSH Terms (2)

---

	Name (Synonyms)	Correlation
D020521	Stroke NIH	0.22
D007239	Infection NIH	0.04

Correlated HPO Terms (1)

---

	Name (Synonyms)	Correlation
HP:0001297	Stroke HPO	0.22

Primary Outcomes

Description: Nature of rehabilitation therapy, and number and duration of rehabilitation therapy sessions

Measure: Rehabilitation data

Time: 3 month after start lockdown

---

Description: Patient-reported upper limb use in daily life

Measure: Motor Activity Log - 14 Item Version

Time: 3 month after start lockdown

---

Description: Patient-reported engagement in physical activity in daily life

Measure: International Physical Activity Questionnaire

Time: 3 month after start lockdown

---

Description: Patient-self-assessment comprising the following categories: 1) physical function, 2) anxiety, 3) depression, 4) fatigue, 5) sleep disturbance, 6) ability to participate in social roles and activities, 7) pain interference and 8) pain intensity

Measure: Patient-Reported Outcomes Measurement Information System - 29 Version

Time: 3 month after start lockdown

---

Secondary Outcomes

Description: Patient-reported global rating of physical activity engagement and upper limb use in daily life

Measure: Global Rating of Perceived Changes (physical activity engagement and upper limb use)

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

---

Description: Self-reported questionnaire regarding severity of fatigue and its influence on the performance of daily life activities

Measure: Fatigue Severity Scale

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

---

Description: Depression and anxiety

Measure: Hospital Anxiety and Depression Scale

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

---

Description: Assesses cognitive functions

Measure: Montreal Cognitive Assessment

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

---

Description: Classification regarding the ability to walk independently, with or without a walking aid and takes the type of walking surface into account

Measure: Functional Ambulation Categories

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

---

Description: Gait speed and cadence

Measure: Ten-Meter Walk Test

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

---

Description: Measures the ability of patients to make postural adjustments (e.g, move in bed), transfer (e.g. be-tween bed to chair), walk, and use stairs

Measure: Rivermead Mobility Index

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

---

Description: Self-reported measure in which patients rate how confident they are in maintaining balance when performing 16 daily life tasks

Measure: Activities-specific Balance Confidence Scale

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

---

Description: Upper and lower limb motor function

Measure: Fugl-Meyer Motor Assessment

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

---

Description: Upper limb capacity

Measure: Action Research Arm Test

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

---

Description: Global disability

Measure: modified Rankin Scale

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

---

Description: Neurological impairments

Measure: National Institutes of Health Stroke Scale

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

---

Description: Nature of rehabilitation therapy, and number and duration of rehabilitation therapy sessions

Measure: Rehabilitation data

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdown

---

Description: Patient-reported upper limb use in daily life

Measure: Motor Activity Log - 14 Item Version

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdown

---

Description: Patient-reported engagement in physical activity in daily life

Measure: International Physical Activity Questionnaire

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdown

---

Description: Patient-self-assessment comprising the following categories: 1) physical function, 2) anxiety, 3) depression, 4) fatigue, 5) sleep disturbance, 6) ability to participate in social roles and activities, 7) pain interference and 8) pain intensity

Measure: Patient-Reported Outcomes Measurement Information System - 29 Version

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdown

---

Primary Outcomes

Description: WHO definition of "influenza-like illness" (ILI) [Fitzner 2018] or confirmed viral/bacterial respiratory infection AND Results in a change or delay in cancer treatment or requirement for and unscheduled medical assesment, hospitalization or death.

Measure: The rate of "flu-like illness" which includes:

Time: 1 year

---

Secondary Outcomes

Measure: The incidence of documented COVID-19 infection (confirmed by any Health Canada approved COVID-19 test. Both symptomatic and asymptomatic infections will be documented

Time: 1 year

---

Measure: The rate of severe respiratory and COVID-19 infection defined as a confirmed COVID-19 infection leading to hospitalization, ICU admission or death

Time: 1 year

---

Measure: The number of events that meet the definition of the primary endpoint, as measured within the one-year follow-up (patients may meet the primary endpoint more than once and be counted multiple times).

Time: 1 year

---

Measure: The incidence of COVID-19 seroconverted patients between baseline, 3 months, 6 months and 12 months

Time: 3, 6, and 12 months

---

Measure: The incremental cost-effectiveness ratio (in the unit of CAD$ per life-years gained) measured with EQ-5D-5L

Time: 1 year

---

Measure: Failure-free survival, as time from enrollment to recurrence or progression declared by the investigator on the basis of objective standard evaluation consistent with the disease site or death

Time: 1 year

---

Measure: Overall survival (OS), as time from enrollment to death from any cause

Time: 1 year

---

Measure: Incidence, frequency, and severity of AEs considered possibly, probably or definitely related to receipt of IMM-101

Time: 1 year

---

Measure: Incidence and frequency of local injection site reactions subsequent to IMM-101 administration

Time: 1 year

---

Measure: Incidence and duration of ICU admission related to documented COVID-19 infection

Time: 1 year

---

HP:0001297: Stroke

Genes 174

TANGO2 JAG1 SMARCAL1 LIMK1 MMUT RFC2 VHL TREX1 PCNT ENG JAK2 TTR CCM2 COX2 COX1 TRNF GTF2I KRAS CPS1 GDF2 SMAD3 TET2 TRNW ABCC6 MFAP5 TGFBR3 APP ELN ADA2 TRNF OTC LMNA LOX FLNA GATA6 CLIP2 ELN XYLT1 APP PNP THPO GNAQ ADA2 SH2B3 TRNC GYS1 F2 SCN5A GATA4 TGFB3 SNAP29 HBB GLA SMAD4 NPPA TRNS2 COL4A1 ACVRL1 TRNK TRNL1 ND1 ND4 TNNT2 KCNQ1 FBN1 COX1 ACVRL1 AGXT COL3A1 TGFBR1 MYPN TGFB2 TRNW APP ALOX5AP PRNP COX3 TRNQ ND5 RFT1 TP53 XYLT2 MYH11 MPL CALR MYBPC3 MECP2 ND6 CST3 CYTB ACTA2 MYD88 ND5 F5 ENG ELN CYTB SMAD4 TRNV SLC2A10 PRKG1 MLXIPL GUCY1A1 HTRA1 TBL2 COX3 MTHFR PRKCH PRKAG2 NR3C1 TREX1 SLC19A2 PIK3C2A APP NR2F2 ZAP70 TGFBR2 WFS1 GLA MYLK APP NOTCH3 TRNS1 COX2 TPP2 COL4A1 KIF20A CBS BAZ1B TRNS2 ANGPTL6 TNXB TRNQ MPL ENG MAT2A JAK2 ZMPSTE24 ASS1 CYP11B1 TET2 SMAD4 MPL TNNI3 ACAD9 ND6 TRNS1 STIM1 HSD11B2 SLC19A2 DYRK1B PMM2 FLNC GTF2IRD1 SON ACTG1 FOXE3 TRNL1 THSD1 NOS3 GUCY1A1 MYH11 ACTB TRNH NAGS HTRA1 PIGA CST3 MYH11 COL3A1 ND1 JAK2 DPM3 CRELD1

Protein Mutations 10

A143T C807T G20210A I843S L33P M235T N215S R112H V34L V66M

SNP 5

rs10033464 rs1906591 rs2106261 rs333 rs6265